close

Agreements

1 202 203 204 205 206 228
Number of results: 4541

Excel print is not allowed for data more than 3000.Please search above for fewer data.

Date Company Compound Disease Type of agreement Therapeutic area Type of Information
2012-04-26 MDxHealth (Belgium) PLUS Diagnostics (USA) ConfirmMDx™ for Prostate Cancer prostate cancer

co-promotion
marketing
commercialisation

Cancer - Oncology Commercialisation agreement
2012-04-26 Evotec (Germany) Active Biotech (Sweden) novel small molecule modulators of a priority biological target involved in immune disorders and cancer cancers, immune diseases

collaboration
R&D

Cancer - Oncology - Immune diseases R&D agreement
2012-04-26 BioAlliance Pharma (France) Herlev Hospital of Copenhagen (Denmark) Amep® (targeted biotherapy)

collaboration
clinical research

Clinical research agreement
2012-04-25 AstraZeneca (UK) The Medicines Company (USA) Brilinta® (ticagrelor) - Angiomax® (bivalirudin) for injection - cangrelor acute ischaemic heart disease, acute coronary syndrome

development
commercialisation
co-promotion

Cardiovascular diseases Development agreement
2012-04-24 Novo Nordisk (Denmark) Oxford University (UK) novel treatments and biomarkers for rheumatoid arthritis and other inflammatory diseases rheumatoid arthritis and other inflammatory diseases Autoimmune diseases – Inflammatory diseases - Rheumatic diseases R&D agreement
2012-04-23 Alnylam Pharmaceuticals (USA - MA) Plant Bioscience Limited (UK) Baulcombe patent (U.S. Patent No. 8,097,710) for use in the field of human therapeutics

licensing

Licensing agreement
2012-04-23 Abcodia (UK) Biouniversa (Italy) BAG3 protein biomarker pancreatic cancer

development

Cancer - Oncology Development agreement
2012-04-19 Sanofi (France) The Michael J. Fox Foundation (USA) AVE 8112 Parkinson’s disease

collaboration
clinical research

Neurodegenerative diseases - CNS diseases Clinical research agreement
2012-04-19 Iris Pharma (France) RxGen (USA) “bench-to-bedside” ophthalmology research services

collaboration

Ophtalmological diseases Collaboration agreement
2012-04-18 Lonza (Switzerland) CSIRO (Australia) new insect silk based products

development

Development agreement
2012-04-18 Selcia (UK) Heptares Therapeutics (UK) fragment ligands that specifically bind to a Family B stabilised GPCR (StaR®) drug target purified by Heptares

collaboration

Collaboration agreement
2012-04-17 Labor L+S (Germany) Symbiosis, newly created unit of BioPharm (Germany) analytical services

collaboration

Collaboration agreement
2012-04-17 Angel Biotechnology (UK) TransGenRx (USA) recombinant interferon product

development

Development agreement
2012-04-17 GSK (UK) Five Prime Therapeutics (USA) refractory asthma
chronic obstructive pulmonary disease (COPD)

R&D

Respiratory diseases - Inflammatory diseases - Allergic diseases R&D agreement
2012-04-16 AstraZeneca (UK) Conformetrix (UK) Conformetrix’s proprietary NMR-based technology

R&D
services

R&D agreement
2012-04-16 Conformetrix (UK) AstraZeneca (UK) Conformetrix’s proprietary NMR-based technology R&D
collaboration
2012-04-12 Lonza (Switzerland) Agennix (Germany) talactoferrin non-small cell lung cancer

development
manufacturing
production

Cancer - Oncology Production agreement
2012-04-12 AstraZeneca (UK) Drugs for Neglected Diseases initiative (DNDi) novel drug candidates Chagas disease, leishmaniasis, sleeping sickness (human African trypanosomiasis)

R&D

Infectious diseases - Parasitic diseases R&D agreement
2012-04-12 Algeta (Norway) Bayer (Germany) Alpharadin® (radium-223 chloride)

promotion

Cancer Oncology Promotion agreement
2012-04-12 Seattle Genetics (USA - WA) Ventana Medical Systems (USA), a member of the Roche Group (Switzerland) molecular companion diagnostic test to evidentify patients who might respond to treatment with Adcetris® (brentuximab vedotin) based on CD30 expression levels in their tissue specimens CD30-positive cutaneous T-cell lymphoma (CTCL), CD30-positive mature T-cell lymphomas (MTCL)

collaboration
development
manufacturing
production
commercialisation

Cancer - Oncology Development agreement